A prospective, randomized, open-label, active-controlled, clinical trial to assess central haemodynamic effects of bisoprolol and atenolol in hypertensive patients

Journal of Hypertension

Volumn 31, Issue 4, 2013, Pages 813-819

  Park, Sungha ^a   Rhee, Moo Yong ^b   Lee, Sung Yun ^c   Park, Seung Woo ^d   Jeon, Dongwoon ^e   Kim, Byung Wook ^c   Kwan, Jun ^c   Choi, Donghoon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Dongguk University Ilsan Hospital   (South Korea)

^c Inje University   (South Korea)

^d Samsung Medical Center   (South Korea)

^e National Health Insurance Corporation   (South Korea)

Author keywords

beta blockers; central blood pressure; central pulse pressure; hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BISOPROLOL;

ADULT; ANTIHYPERTENSIVE THERAPY; AORTA PRESSURE; AORTA PULSE PRESSURE; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BRACHIAL ARTERY; BRACHIAL BLOOD PRESSURE; BRADYCARDIA; CENTRAL PULSE PRESSURE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMODYNAMICS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; PULSE WAVE; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; TONOMETRY; TREATMENT DURATION; VASCULAR RESISTANCE;

EID: 84875225041     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835e8f5b     Document Type: Article

References (20)

1. Dahlo?f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995- 1003.
2. Dahlo?f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
3. Ong H. ß-blockers in hypertension and cardiovascular disease. BMJ 2007; 334:946-949.
4. Khan N, McAlister FA. Re-examining the efficacy of ß blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174:1737-1742.
5. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al., for the CAFÉ investigators. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes-principal results of the Conduit Artery Function Evaluation Study: the CAFÉ study. Circulation 2006; 113:1213-1225.
6. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
7. Coleman A, Steel S, Freeman P, de Greeff A, Shennan A. Validation of the Omron M7 (HEM 780-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Press Monit 2008; 13:49-54.
8. Yang WI, Park S, Youn JC, Son NH, Lee SH, Kang SM, Jang Y. Augmentation index association with reactive hyperemia as assessed by peripheral arterial tonometry in hypertension. Am J Hypertens 2011; 24:1234-1238.
9. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R, Eber B. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 2004; 109:184-189.
10. Weber T, O'Rourke MF, Ammer M, Kvas E, Punzengruber C, Eber B. Arterial stiffness and arterial wave reflections are associated with systolic and diastolic function in patients with normal ejection fraction. Am J Hypertens 2008; 21:1194-1202.
11. Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol 2008; 105:1652-1660.
12. Casey DP, Curry TB, Joyner MJ, Charkoudian N, Hart EC. Acute ß-adrenergic blockade increases aortic wave reflection in young men and women: differing mechanisms between sexes. Hypertension 2012; 59:145-150.
13. Ting CT, Chen CH, Chang MS, Yin FC. Short and long term effects of antihypertensive drugs on arterial reflections, compliance, and impedance. Hypertension 1995; 26:524-530.
14. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular thickness. Hypertension 2011; 57:1122-1128.
15. Cockroft JR, Chowiencyzk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO dependent mechanism. J Pharmacol Exp Therap 1995; 274:1067-1071.
16. Dhakam Z, Yasmin, McEinery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26:351-356.
17. Mahmud A, Feely J. ß-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008; 21:663-667.
18. Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS, Levy D. Predictors of new onset diastolic and systolic hypertension. Circulation 2005; 111:1121-1127.
19. Kneale BJ, Chowienczyk PJ, Brett SE, Coltart DJ, Ritter JM. Gender differences in sensitivity to adrenergic agonists of forearm resistance vasculature. J Am Coll Cardiol 2000; 36:1233- 1238.
20. Boutouyrie P, Achouba A, Trunet P, Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010; 55:1314-1322.